FEVERFEW: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Feverfew (Tanacetum parthenium) is a plant native to Asia Minor and the Balkans. Feverfew dried leaves, fresh leaves, and extracts are used in medicine.

Feverfew leaves contain many different chemicals, including one called parthenolide. Parthenolide, as well as other chemicals in feverfew, might help decrease migraine headaches.

People most commonly use feverfew for migraine headaches. People also use feverfew for itching, tension headache, and many other conditions, but there is no good scientific evidence to support these uses.

Uses & Effectiveness

Possibly Effective for

Migraine. Taking feverfew by mouth, alone or with other ingredients, can reduce the frequency and duration of migraine headaches. It might also reduce pain, nausea, vomiting, and sensitivity to light and noise.

There is interest in using feverfew for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Side Effects

When taken by mouth: Dried feverfew leaf or feverfew extract is likely safe when taken for up to 4 months. Side effects might include upset stomach, heartburn, diarrhea, constipation, bloating, and vomiting.

Chewing the fresh leaves of feverfew is possibly unsafe. It can cause mouth sores, swelling of the mouth, and loss of taste.

Special Precautions and Warnings

Pregnancy: Feverfew is possibly unsafe when taken by mouth during pregnancy. There is concern that it might cause early contractions and miscarriage. Don't use feverfew if you are pregnant.

Breast-feeding: There isn't enough reliable information to know if feverfew is safe to use when breast-feeding. Stay on the safe side and avoid use.

Bleeding disorders: Feverfew might slow blood clotting. Taking feverfew could increase the risk of bleeding in some people. Until more is known, use feverfew cautiously if you have a bleeding disorder.

Allergy to ragweed and related plants: Feverfew might cause an allergic reaction in people who are sensitive to the Asteraceae/Compositae plant family. This includes ragweed, chrysanthemums, marigolds, daisies, and many others. If you have allergies, be sure to check with your healthcare provider before taking feverfew.

Surgery: Feverfew might slow blood clotting. It might cause bleeding during and after surgery. Stop taking feverfew at least 2 weeks before a scheduled surgery.

Interactions

Moderate Interaction

Be cautious with this combination

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with FEVERFEW
Some medications are changed and broken down by the liver. Feverfew might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with FEVERFEW
Some medications are changed and broken down by the liver. Feverfew might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with FEVERFEW
Some medications are changed and broken down by the liver. Feverfew might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with FEVERFEW
Some medications are changed and broken down by the liver. Feverfew might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with FEVERFEW
Feverfew might slow blood clotting. Taking feverfew along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
Medications changed by the liver (Cytochrome P450 2C8 (CYP2C8) substrates) interacts with FEVERFEW
Some medications are changed and broken down by the liver. Feverfew might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with FEVERFEW
Some medications are changed and broken down by the liver. Feverfew might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.

Dosing

Feverfew has most often been used by adults in doses of 50-150 mg by mouth daily for up to 4 months. Speak with a healthcare provider to find out what dose might be best for a specific condition.

View References

REFERENCES:

Girola M, De Bernardi M, and Contos S, et al. Dose effect in lipid-lowering activity of a new dietary integrator (chitosan, Garcinia cambogia extract and chrome). Acta Toxicol Ther 1996;17(1):25-40.

Glinsmann, W. H. and Mertz, W. Effect of trivalent chromium on glucose tolerance. Metabolism 1966;15(6):510-520. View abstract.

Granchi, D., Verri, E., Ciapetti, G., Savarino, L., Cenni, E., Gori, A., and Pizzoferrato, A. Effects of chromium extract on cytokine release by mononuclear cells. Biomaterials 1998;19(1-3):283-291. View abstract.

Hambidge, K. M., Franklin, M. L., and Jacobs, M. A. Changes in hair chromium concentrations with increasing distances from hair roots. Am J Clin Nutr. 1972;25(4):380-383. View abstract.

Hambidge, K. M., Franklin, M. L., and Jacobs, M. A. Hair chromium concentration: effects of sample washing and external environment. Am J Clin Nutr. 1972;25(4):384-389. View abstract.

Hambidge, K. M., Rodgerson, D. O., and O'Brien, D. Concentration of chromium in the hair of normal children and children with juvenile diabetes mellitus. Diabetes 1968;17(8):517-519. View abstract.

Hasten, D. L., Rome, E. P., Franks, B. D., and Hegsted, M. Effects of chromium picolinate on beginning weight training students. Int.J.Sport Nutr. 1992;2(4):343-350. View abstract.

Hermann J, Arquitt A, and Stoecker B. Effects of chromium supplementation on plasma lipids, apolipoproteins, and glucose in elderly subjects. Nutrition Research 1994;14(5):671-674.

Hisatomi, K., Ishii, H., Hashiguchi, K., Seki, M., Ide, M., Sugiyama, K., Ishimoto, H., Nakayama, S., Mukae, H., and Kohno, S. Interstitial pneumonia caused by inhalation of fumes of nickel and chrome. Respirology. 2006;11(6):814-817. View abstract.

Hockney, R. A., Montgomery, P., Williams, C., Geddes, J. R., and Cowen, P. J. Lack of effect of chromium supplementation on mental state and body weight in people with schizophrenia. J Clin.Psychopharmacol. 2006;26(5):544-545. View abstract.

Huszonek, J. Over-the-counter chromium picolinate. Am J Psychiatry 1993;150(10):1560-1561. View abstract.

Iqbal, N., Cardillo, S., Volger, S., Bloedon, L. T., Anderson, R. A., Boston, R., and Szapary, P. O. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr.Relat Disord. 2009;7(2):143-150. View abstract.

Jain, S. K., Kahlon, G., Morehead, L., Dhawan, R., Lieblong, B., Stapleton, T., Caldito, G., Hoeldtke, R., Levine, S. N., and Bass, P. F., III. Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-alpha, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study. Mol.Nutr.Food Res. 2012;56(8):1333-1341. View abstract.

Jeejeebhoy, K. N. The role of chromium in nutrition and therapeutics and as a potential toxin. Nutr Rev. 1999;57(11):329-335. View abstract.

Jeejeebhoy, K. N., Chu, R. C., Marliss, E. B., Greenberg, G. R., and Bruce-Robertson, A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977;30(4):531-538. View abstract.

Joseph, L. J., Farrell, P. A., Davey, S. L., Evans, W. J., and Campbell, W. W. Effect of resistance training with or without chromium picolinate supplementation on glucose metabolism in older men and women. Metabolism 1999;48(5):546-553. View abstract.

Jovanovic L, Gutierrez M, and Peterson CM. Chromium supplementation for women with gestational diabetes mellitus. J Trace Elem Exp Med 1999;12(2):91-97.

Jovanovic-Peterson L, Gutierrez M, and Peterson CM. Chromium supplementation for gestational diabetic women (GDM) improves glucose tolerance and decreases hyperinsulinemia [abstract]. Diabetes 1996;45(Suppl 2):337A.

Kaats GR, Blum K, Fisher JA, and et al. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. Current Therapeutic Research 1996;57(10):747-756.

Kaats GR, Blum K, Pullin D, and et al. A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Current Therapeutic Research 1998;59(6):379-388.

Kaats GR. The short term therapeutic efficacy of treating obesity with a plan of improved nutrition and moderate calorie restriction. Curr Ther Res 1992;51:261-274.

Kato, I., Vogelman, J. H., Dilman, V., Karkoszka, J., Frenkel, K., Durr, N. P., Orentreich, N., and Toniolo, P. Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil. Eur.J Epidemiol. 1998;14(6):621-626. View abstract.

Kelly GS. Sports nutrition: A review of selected nutritional supplements for bodybuilders and strength athletes. Alt Med Rev 1997;2(3):184-201.

Kelly, G. S. Insulin resistance: lifestyle and nutritional interventions. Altern.Med Rev 2000;5(2):109-132. View abstract.

Keszthelyi, Z., Past, T., Koltai, K., Szabo, L., and Mozsik, G. [Chromium (III)-ion enhances the utilization of glucose in type-2 diabetes mellitus]. Orv.Hetil. 10-19-2003;144(42):2073-2076. View abstract.

Kim, C. W., Kim, B. T., Park, K. H., Kim, K. M., Lee, D. J., Yang, S. W., and Joo, N. S. Effects of short-term chromium supplementation on insulin sensitivity and body composition in overweight children: randomized, double-blind, placebo-controlled study. J.Nutr.Biochem. 2011;22(11):1030-1034. View abstract.

Kleefstra, N., Houweling, S. T., Bakker, S. J., Verhoeven, S., Gans, R. O., Meyboom-de Jong, B., and Bilo, H. J. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2007;30(5):1092-1096. View abstract.

Kozlovsky, A. S., Moser, P. B., Reiser, S., and Anderson, R. A. Effects of diets high in simple sugars on urinary chromium losses. Metabolism 1986;35(6):515-518. View abstract.

Krikorian, R., Eliassen, J. C., Boespflug, E. L., Nash, T. A., and Shidler, M. D. Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr.Neurosci. 2010;13(3):116-122. View abstract.

Krol, E., Krejpcio, Z., Byks, H., Bogdanski, P., and Pupek-Musialik, D. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol.Trace Elem.Res. 2011;143(2):726-737. View abstract.

Lai, M. H. Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and e supplementation for type 2 diabetes mellitus. J Clin Biochem.Nutr 2008;43(3):191-198. View abstract.

Lane B. Diet and the glaucomas [abstract]. J Am Coll Nutr. 1991;10:536.

Lees, P. S. Chromium and disease: review of epidemiologic studies with particular reference to etiologic information provided by measures of exposure. Environ Health Perspect. 1991;92:93-104. View abstract.

Lefavi RG, Wilson GD, Keith RE, and et al. Lipid-lowering effect of a dietary chromium (III) - nicotinic acid complex in male athletes. Nutrition Research 1993;13:239-249.

Levine, R. A., Streeten, D. H., and Doisy, R. J. Effects of oral chromium supplementation on the glucose tolerance of elderly human subjects. Metabolism 1968;17(2):114-125. View abstract.

Li, Chen T., LaCerte, C., Wise, S. S., Holmes, A., Martino, J., Wise, J. P., Jr., Thompson, W. D., and Wise, J. P., Sr. Comparative cytotoxicity and genotoxicity of particulate and soluble hexavalent chromium in human and sperm whale (Physeter macrocephalus) skin cells. Comp Biochem.Physiol C.Toxicol.Pharmacol. 2012;155(1):143-150. View abstract.

Li, Chen T., Wise, S. S., Holmes, A., Shaffiey, F., Wise, J. P., Jr., Thompson, W. D., Kraus, S., and Wise, J. P., Sr. Cytotoxicity and genotoxicity of hexavalent chromium in human and North Atlantic right whale (Eubalaena glacialis) lung cells. Comp Biochem.Physiol C.Toxicol.Pharmacol. 2009;150(4):487-494. View abstract.

Littlefield, D. Chromium decreases blood glucose in a patient with diabetes. J Am Diet Assoc 1994;94(12):1368. View abstract.

Livolsi, J. M., Adams, G. M., and Laguna, P. L. The effect of chromium picolinate on muscular strength and body composition in women athletes. J.Strength.Cond.Res. 2001;15(2):161-166. View abstract.

Lucidi, R. S., Thyer, A. C., Easton, C. A., Holden, A. E., Schenken, R. S., and Brzyski, R. G. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil.Steril. 2005;84(6):1755-1757. View abstract.

Lukaski, H. C. Chromium as a supplement. Annu.Rev.Nutr. 1999;19:279-302. View abstract.

Lukaski, H. C. Magnesium, zinc, and chromium nutriture and physical activity. Am J Clin Nutr. 2000;72(2 Suppl):585S-593S. View abstract.

Lukaski, H. C., Siders, W. A., and Penland, J. G. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutrition 2007;23(3):187-195. View abstract.

Martin, W. R. and Fuller, R. E. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy 1998;18(4):860-862. View abstract.

Martinez OB, MacDonald AC, Gibson RS, and et al. Dietary chromium and effect of chromium suppelmentation on glucose tolerance of elderly canadian women. Nutrition Research 1985;5:609-620.

McArdle WD and Moore BJ. Chromium shows little proof as weight loss supplement. Altern Med Alert 1998;1:9-10.

McCarty, M. F. Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. Med Hypotheses 1995;45(3):241-246. View abstract.

McCarty, M. F. Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. Med Hypotheses 1996;46(2):77-80. View abstract.

McCarty, M. F. Complementary measures for promoting insulin sensitivity in skeletal muscle. Med Hypotheses 1998;51(6):451-464. View abstract.

McCarty, M. F. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy-- preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline. Med Hypotheses 1998;50(5):435-449. View abstract.

McLeod, M. N. and Golden, R. N. Chromium treatment of depression. Int J Neuropsychopharmacol 2000;3(4):311-314. View abstract.

Mertz, W. Chromium in human nutrition: a review. J Nutr 1993;123(4):626-633. View abstract.

Mertz, W. Confirmation: chromium levels in serum, hair, and sweat decline with age. Nutr Rev. 1997;55(10):373-375. View abstract.

Morris BW. Chromium action and glucose homeostasis. J Trace Elem Exptl Med 1999;12(2):61-70.

Morris, B. W., MacNeil, S., Hardisty, C. A., Heller, S., Burgin, C., and Gray, T. A. Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 1999;13(1-2):57-61. View abstract.

Mossop, R. T. Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics. Cent.Afr.J Med 1983;29(4):80-82. View abstract.

Nahas, R. and Moher, M. Complementary and alternative medicine for the treatment of type 2 diabetes. Can Fam.Physician 2009;55(6):591-596. View abstract.

Nath R, Minocha J, Lyall V, and et al. Assessment of chromium metabolism in maturity onset and juvenile diabetes using chromium-51 and therapeutic response of chromium administration on plasma lipids, glucose tolerance and insulin levels. In: Shapcott D and Hubert J. Chromium in Nutrition and Metabolism. Amsterdam: Elsevier/North-Holland Biomedical Press;1979.

Newman, H. A., Leighton, R. F., Lanese, R. R., and Freedland, N. A. Serum chromium and angiographically determined coronary artery disease. Clin Chem. 1978;24(4):541-544. View abstract.

Noda, S., Asano, Y., and Sato, S. Lichen planus in a patient with long-term exposure to chrome. Eur.J.Dermatol. 2011;21(3):417-418. View abstract.

O'Flaherty, E. J., Kerger, B. D., Hays, S. M., and Paustenbach, D. J. A physiologically based model for the ingestion of chromium(III) and chromium(VI) by humans. Toxicol.Sci 2001;60(2):196-213. View abstract.

O'Mathuna DP. Chromium supplementation for weight loss. Alternative Medicine Alert 2001;4(4):37-48.

Offenbacher E, Miou J Moussas A Pi-Sunyer F. Chromium (Cr) intake and urinary Cr excretion in young adults. Fed Proc 1985;44(1848):8393.

Offenbacher, E. G. and Pi-Sunyer, F. X. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 1980;29(11):919-925. View abstract.

Offenbacher, E. G. and Pi-Sunyer, F. X. Chromium in human nutrition. Annu.Rev.Nutr. 1988;8:543-563. View abstract.

Offenbacher, E. G. Chromium in the elderly. Biol.Trace Elem.Res. 1992;32:123-131. View abstract.

Offenbacher, E. G., Rinko, C. J., and Pi-Sunyer, F. X. The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects. Am J Clin Nutr 1985;42(3):454-461. View abstract.

Opala, T., Rzymski, P., Pischel, I., Wilczak, M., and Wozniak, J. Efficacy of 12 weeks supplementation of a botanical extract-based weight loss formula on body weight, body composition and blood chemistry in healthy, overweight subjects--a randomised double-blind placebo-controlled clinical trial. Eur J Med Res 8-30-2006;11(8):343-350. View abstract.

Pei, D., Hsieh, C. H., Hung, Y. J., Li, J. C., Lee, C. H., and Kuo, S. W. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism 2006;55(7):923-927. View abstract.

Pekarek, R. S., Hauer, E. C., Rayfield, E. J., Wannemacher, R. W., and Beisel, W. R. Relationship between serum chromium concentrations and glucose utilization in normal and infected subjects. Diabetes 1975;24(4):350-353. View abstract.

Pittler, M. H. and Ernst, E. Complementary therapies for reducing body weight: a systematic review. Int.J.Obes.(Lond) 2005;29(9):1030-1038. View abstract.

Pittler, M. H. and Ernst, E. Dietary supplements for body-weight reduction: a systematic review. Am.J.Clin Nutr. 2004;79(4):529-536. View abstract.

Pohl, M., Mayr, P., Mertl-Roetzer, M., Lauster, F., Haslbeck, M., Hipper, B., Steube, D., Tietjen, M., Eriksen, J., and Rahlfs, V. W. Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial. JPEN J.Parenter.Enteral Nutr. 2009;33(1):37-49. View abstract.

Awang DV. Parthenocide: the demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5(4):95-98.

Burry, J. N. Compositae dermatitis in South Australia: contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980;6(6):445. View abstract.

Christensen, L. P., Jakobsen, H. B., Paulsen, E., Hodal, L., and Andersen, K. E. Airborne Compositae dermatitis: monoterpenes and no parthenolide are released from flowering Tanacetum parthenium (feverfew) plants. Arch Dermatol Res 1999;291(7-8):425-431. View abstract.

Czyz, M., Lesiak-Mieczkowska, K., Koprowska, K., Szulawska-Mroczek, A., and Wozniak, M. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br.J.Pharmacol. 2010;160(5):1144-1157. View abstract.

De Weerdt, C. J., Bootsma, H. P., and Hendriks, H. Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225-230. View abstract.

DeWeerdt CJ, Bootsman H, and Hendricks H. Herbal medicines in migraine prevention. Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomed 1996;3(3):225-230.

Gromek, D., Kisiel, W., Stojakowska, A., and Kohlmunzer, S. Attempts of chemical standardizing of Chrysanthemum parthenium as a prospective antimigraine drug. Pol.J.Pharmacol.Pharm. 1991;43(3):213-217. View abstract.

Hayes, N. A. and Foreman, J. C. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol 1987;39(6):466-470. View abstract.

Jovanovic, M. and Poljacki, M. [Compositae dermatitis]. Med Pregl. 2003;56(1-2):43-49. View abstract.

Kemper, K. J. and Breuner, C. C. Complementary, holistic, and integrative medicine: headaches. Pediatr.Rev. 2010;31(2):e17-e23. View abstract.

Kuritzky A, Elhacham Y, Yerushalmi Z, and et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):A201.

Loder, E., Burch, R., and Rizzoli, P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52(6):930-945. View abstract.

Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap.Minn.) 2012;18(4):796-806. View abstract.

Modi, S. and Lowder, D. M. Medications for migraine prophylaxis. Am Fam.Physician 1-1-2006;73(1):72-78. View abstract.

Palevitch D, Earon G, and Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997;11(7):508-511.

Pfaffenrath V, Fischer M, Friede M, and et al. Clinical dose-response study for the investigation of efficacy and tolerability of Tanacetum parthenium in migraine prophylaxis. Deutscher Schmerzkongress; October 20-24, 1999, Munich, Germany. 1999;

Silberstein, S. D. Preventive treatment of headaches. Curr Opin Neurol. 2005;18(3):289-292. View abstract.

Waller, P. C. and Ramsay, L. E. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 10-19-1985;291(6502):1128. View abstract.

Alenzi KA, Alharbi FH, Tawhari FM, Fradees GS. Alteration of Coagulation Test Results and Vaginal Bleeding Associated With the Use of Feverfew (Tanacetum parthenium). J Med Cases 2021;12(1):9-12. View abstract.

Awang DV. Parthenocide: demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5:95-8.

Awang DVC. Prescribing therapeutic feverfew (Tancetum pathrnium (L.) Schultz Bip., syn. Chrysanthemumparthenium (L.) Bernh). Int Med 1998;1:11-3.

Barsby R, Salan U, Knight DW, Hoult JR. Irreversible inhibition of vascular reactivity by feverfew. Lancet 1991;338:1015. View abstract.

Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol 1992;44:737-40. View abstract.

Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;2:776. View abstract.

Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-9. View abstract.

Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic M) in the treatment of migraine. Headache 2011;51:1078-86. View abstract.

Cady RK, Schreiber CP, Beach ME, et al. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Med Sci Monit. 2005;11:I65-69. View abstract.

Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet 1980;2:922-3. View abstract.

de Weerdt GJ, Bootsman HPR, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind, placebo-controlled, crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-30.

Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005;25:1031-41. View abstract.

Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000;3:509-14. View abstract.

Ferro EC, Biagini AP, da Silva ÍE, Silva ML, Silva JR. The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: randomised study. Acupunct Med. 2012 Dec;30(4):252-7. View abstract.

Foster S. Feverfew, Tanacetum parthenium, botanical series #310. Austin, TX: Am Botanical Council, 1996.

Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol 1990;42:553-7. View abstract.

Guilbot A, Bangratz M, Ait Abdellah S, Lucas C. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med. 2017;17(1):433. doi: 10.1186/s12906-017-1933-7. View abstract.

Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol 1987;39:459-65. View abstract.

Heptinstall S, Groenewegen WA, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphydryl groups. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:447-9. View abstract.

Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985;1:1071-4. View abstract.

Heptinstall S. Feverfew--an ancient remedy for modern times? J R Soc Med. 1988 Jul;81(7):373-4. View abstract.

Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53. View abstract.

Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810-8.. View abstract.

Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol 1999;68:251-9. View abstract.

Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985;291:569-73. View abstract.

Kuritzky A, Elhacham Y, Yerushalmi Z, et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):A201. (Abstract 293P)

Lamminpaa A, Estlander T, Jolanki R, Kanerva L. Occupational allergic contact dermatitis caused by decorative plants. Contact Dermatitis 1996;34:330-5. View abstract.

Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44:885-90. View abstract.

Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med 1982;8:653-60. View abstract.

Makheja AN, Bailey JM. The active principle in feverfew. Lancet 1981;2:1054. View abstract.

McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: overview of program description and methodology. US Headache Consortium, April 2000. Available at: www.aan.com/cgi-bin/whatsnewlink.pl?loc=/public/practiceguidelines.

Moscano F, Guiducci M, Maltoni L, et al. An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache. Ital J Pediatr. 2019;45(1):36. View abstract.

Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9. View abstract.

Murphy JJ, Heptinstall S, Mitchell JR. Randomized, double-blind, placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-92. View abstract.

Palevitch D, Earon G, Carasso R. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine- a double-blind, placebo-controlled study. Phytotherapy Res 1997;11:508-11.

Pareek A, Suthar M, Rathore G, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev. 2011;5(9):103-110. View abstract.

Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double-blind, placebo-controlled study. Ann Rheum Dis 1989;48:547-9. View abstract.

Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-32. View abstract.

Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004;(1):CD002286. View abstract.

Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2000;3:CD002286. View abstract.

Prusinski A, Durko A, and Niczyporuk-Turek A. [Feverfew as a prophylactic treatment of migraine]. Neurol.Neurochir.Pol. 1999;33 Suppl 5:89-95. View abstract.

Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988;40:743-5. View abstract.

Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126-9. View abstract.

Saraceno R, Chiricozzi A, Nistico SP, et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J.Dermatolog.Treat. 2010;21:363-66. View abstract.

Shrivastava R, Pechadre JC, and John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig. 2006;26:287-96. View abstract.

Sil'vestrov VP, Kinitin AV, and Chesnokova, IV. [Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis]. Ter.Arkh. 1991;63:7-11. View abstract.

Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992;43:2313-20. View abstract.

Sun-Edelstein, C. and Mauskop, A. Foods and supplements in the management of migraine headaches. Clin J Pain 2009;25(5):446-452. View abstract.

Sur R, Martin K, Liebel F, et al. Anti-inflammatory activity of parthenolide-depleted Feverfew (Tanacetum parthenium). Inflammopharmacology. 2009;17:42-9. View abstract.

Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18:2273-81. View abstract.

Vikelis M, Dermitzakis EV, Vlachos GS, et al. Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis. J Clin Med 2020;10(1):67. View abstract.

Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18:704-8. View abstract.

Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015 Apr 20;4:CD002286. [Epub ahead of print] View abstract.

Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry 1999;51:417-23. View abstract.

Williams CA, Hoult JR, Harborne JB, et al. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry 1995;38:267-70. View abstract.

Wong HC. Is feverfew a pharmacologic agent? CMAJ 1999;160:21-2. View abstract.

Zavarize P, Ngonga G, Pezzini A, Dalla Volta G. Combination of tanacethum partenium, 5-hjydrossitriptophan (5-Http) and magnesium in the prophylaxis of episodic migraine without aura (AURASTOP®) an observational study. Int J Neuro Brain Dis 2017;4(3):1-4. DOI: 10.15436/2377-1348.17.1630

Infusion Therapy for Migraine: What You Need to Know

High-Frequency Episodic Migraine: More Than a Bad Headache

Alternative Treatments for Migraines

Is Migraine Infusion Therapy Right for You?

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.

FEVERFEW - Uses, Side Effects, and More

Overview

Uses & Effectiveness

Possibly Effective for

Side Effects

Special Precautions and Warnings

Interactions

Moderate Interaction

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with FEVERFEW

Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with FEVERFEW

Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with FEVERFEW

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with FEVERFEW

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with FEVERFEW

Medications changed by the liver (Cytochrome P450 2C8 (CYP2C8) substrates) interacts with FEVERFEW

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with FEVERFEW

Dosing

You Might Also Like